News

Researchers relied on support from ORNL’s Quantum Computing User Program to simulate a key quantum state at one of the largest scales reported. The findings could mark a step toward improving quantum simulations. Credit: Getty Images
Steering toward quantum simulation at scale
PowerGrid Auburn University
Auburn, ORNL to partner on grid security
Three ORNL researchers receive Outstanding Young Manufacturing Engineer Award
Researchers receive SME awards

Filter News

Area of Research

News Type

Date

News Topics

Media Contacts

Connect with ORNL

Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy

ORNL meets key FDA milestone for cancer-fighting Ac-225 isotope

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.

Radiochemical technicians David Denton and Karen Murphy use hot cell manipulators at Oak Ridge National Laboratory during the production of actinium-227.

ORNL ramps up production of key radioisotope for cancer-fighting drug

The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.

COHERENT collaborators were the first to observe coherent elastic neutrino–nucleus scattering. Their results, published in the journal Science, confirm a prediction of the Standard Model and establish constraints on alternative theoretical models. Image c

World’s smallest neutrino detector finds big physics fingerprint

After more than a year of operation at the Department of Energy’s (DOE’s) Oak Ridge National Laboratory (ORNL), the COHERENT experiment, using the world’s smallest neutrino detector, has found a big fingerprint of the elusive, electrically neutral particles that interact only weakly with matter.